RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
The viewer aims to help radiologists work smarter, faster, and more collaboratively, while reducing IT complexity and freeing up valuable clinical time
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Valneva will consolidate its French operations at its Lyon site and close its Nantes location
Owlet’s push comes as parents demand smarter, more dependable nursery tech
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Subscribe To Our Newsletter & Stay Updated
